Sampre Nutritions Share Price Hits Upper Circuit After Reporting 615% Profit Growth in Q1FY26

Sampre Nutritions Limited, a prominent name in the Indian confectionery sector, has released its financial results for the quarter ended June 30, 2025. 

The company’s performance in the first quarter of FY26 has attracted market attention after posting substantial year-on-year and sequential growth in both revenue and net profit.

Sampre Nutritions Q1FY26 Results

Sampre Nutritions Limited reported revenue from operations of ₹10.87 crore in Q1FY26, registering a 141% year-on-year growth from ₹4.51 crore reported in Q1FY25.

The net profit soared to ₹70.76 lakh, a 615% increase compared to ₹9.89 lakh in the corresponding quarter of the previous year. The earnings per share (EPS) stood at ₹0.34 versus ₹0.11 in Q1FY25.

Management Commentary Highlights Strategic Execution

Commenting on the performance, the company stated, “We are happy to report such stellar results with 615% growth in Net Profit on a Year-on-Year basis. The financial growth and improved margins clearly illustrate our strategic initiatives, operational efficiency and financial planning. We are looking forward to continuing this growth momentum, with focus on strengthening our market position.”

The sharp improvement in margins and profitability points towards successful execution of strategies and cost optimisation.

Fundraising Plans Underway to Support Expansion

To support its future growth and diversification, Sampre Nutritions has proposed a fundraising initiative. The company is exploring various modes including preferential issue, qualified institutional placement (QIP), and public or private offerings.

As per a prior update to BSE, a board meeting will be scheduled to seek shareholder approval for the capital raise. This move aims to strengthen the financial structure and fuel the next phase of expansion.

Notably, in November 2024, the company had approved the allotment of 8.4 lakh warrants to non-promoters at a price of ₹60.50 per warrant, convertible into one equity share each.

Sampre Nutritions Share Price Performance 

On July 22, 2025, at 2:32 PM, Sampre Nutritions share price hit a 2% upper circuit and was trading at ₹47.04 per share. 

Read More: Govt's ₹60,000 Crore ITI Upgrade Plan Draws Big Names Like Reliance, Adani, Mahindra! 

About Sampre Nutritions Limited

Founded in 1991 and based in Medchal, Telangana, Sampre Nutritions Limited manufactures a full range of confectionery products including éclairs, candies, lollipops, toffees, powder and centre-filled treats. It is a preferred manufacturing partner for several multinational corporations such as Mondelez India, Perfetti Van Melle, Nestlé, DS Group and Reliance.

Sampre Nutritions holds the distinction of being the first ISO certified confectionery company in South East Asia since 1995. It is also the first company in its segment to be HACCP certified by BVQI, along with being FSSA Version 6 certified and a recipient of multiple global quality awards.

Of particular note is its 30-year relationship with Mondelez India, where it has been the sole manufacturer of éclairs for India, China, and South Africa for the past eight years. The promoter of the company also holds the position of President of the Indian Confectionery Manufacturers Association and brings four decades of industry experience.

Conclusion 

Sampre Nutritions’ quarterly results have resulted in share price hitting the upper circuit. Investors have taken note of the developments, although future performance will depend on consistent delivery and effective execution of its expansion plans.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities are subject to market risks. Read all related documents carefully before investing.